Results 161 to 170 of about 13,859,723 (285)

Approach to the spectrum of infant non-IgE-mediated food allergy manifestations and physiologic infant behaviors. [PDF]

Curr Probl Pediatr Adolesc Health Care
Herman K, Järvinen KM.
europepmc   +1 more source

The External Exposome and Food Allergy: How Environmental Exposures Shape Disease Risk

Allergy, EarlyView.
ABSTRACT IgE‐mediated food allergy is a global health issue with rising prevalence that cannot be explained by genetic change alone, strongly suggesting that environmental exposures are a key driver. The external exposome encompasses several exposures that influence the developing immune system and modify food allergy risk.
Johanna M. Smeekens, Helen A. Brough, Kirsi M. Järvinen, Sophie Troyer, Michael D. Kulis, Timothy P. Moran   +5 more
wiley   +1 more source

Failed Mucosal Allostasis Distinguishes Murine IgG‐ From IgE‐Mediated Recurrent Severe Anaphylaxis

Allergy, EarlyView.
This study investigates IgE‐ and IgG‐mediated pathways in acute and recurrent anaphylaxis using a murine ASA‐PSA model, assessing barrier integrity, immune activation and tissue remodelling across pulmonary and intestinal compartments. Recurrent IgE‐ and IgG‐mediated anaphylaxis produces divergent mucosal outcomes despite comparable systemic severity ...
Abdurrahman Simsek, Muhammed Ali Kizmaz, Tugce Bozkurt, Sude Toprakkaz, Mehmet Emre Topcu, Musa Ozgur Ozyigit, Ahmet Akkoc, Dane Ediger, Ferah Budak Sener   +8 more
wiley   +1 more source

IgE‐Binding Bacterial Components Not Yet Documented in the Allergen Databases and Their Allergenic Mechanisms: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Among bacteria that are associated with the development and/or exacerbation of allergic/atopic diseases, several have been described to produce IgE‐binding components. However, only one bacterial protein, Bac s 1, is currently listed in the official database of the World Health Organization/International Union of Immunological Societies (WHO ...
Uta Jappe, Marua Abu Risha, Ioana Agache, Claus Bachert, Barbara Bröker, Riccardo Castagnoli, Gabriele Gadermaier, Richard E. Goodman, Amir Guemari, Christiane Hilger, Alain Jacquet, Sabine Kespohl, Ludger Klimek, Annette Kuehn, Jonas Lidholm, Vera Mahler, Markus Ollert, Thomas A. Platts‐Mills, Monika Raulf, Peter Schmid‐Grendelmeier, Frieder Schmiedeke, Marianne van Hage, Joana Vitte, Josefina Zakzuk, Anna Pomés   +24 more
wiley   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Expanding the Utility of Gold Nanocluster “Allergolds” to Peanut Allergen Ara h 2

Allergy, EarlyView.
Gage O. Leighton, Victor Martinez‐Macias, Emmanuel R. De Diavoukana, Adalia Wambolt, Xunyang Chen, Scott A. Gabel, Scott A. Smith, Sarita U. Patil, Geniece Hallett‐Tapley, Alexander C. Y. Foo, Geoffrey A. Mueller   +10 more
wiley   +1 more source

Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy

Allergy, EarlyView.
In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...
Marie‐Lee Simard, Camille Braun, Éloise Antony, Émilie Roy, Marie‐Ève Gingras, François Graham, Anne Des Roches, Louis Paradis, Kathryn Samaan, Florence Gingras‐Lessard, Roxane Labrosse, Thomas Eiwegger, Philippe Bégin   +12 more
wiley   +1 more source

Update on Selected Adverse Events of Concern Following Immunization With Acellular Pertussis Vaccines, a Narrative Review

Acta Paediatrica, EarlyView.
ABSTRACT Aim To provide an update paper on evidence of adverse events of concern following immunization (AEFI) with pertussis vaccines, focusing primarily on acellular (aP) vaccines. Methods Evidence was synthesised from epidemiological studies, systematic reviews over recent decades, expert interpretations in reviews from relevant research teams and ...
Lennart Nilsson, Jann Storsaeter
wiley   +1 more source

Biomarkers Predicting Sustained Unresponsiveness After Oral Immunotherapy in the OPIA Trial

Allergy, EarlyView.
Duan Ni, Gabriela Pinget, Brigitte Santner‐Nanan, Catherine L. Lai, Laurence Macia, Dianne E. Campbell, Peter Hsu, Ralph Nanan   +7 more
wiley   +1 more source

Safety and Clinical Outcomes of High‐ Versus Low‐Dose Oral Peanut Immunotherapy in Polish Children With Peanut Allergy

Acta Paediatrica, EarlyView.
ABSTRACT Aim To compare safety and clinical outcomes of two different oral immunotherapy (OIT) maintenance doses (150 mg vs. 300 mg) of peanut protein in children with peanut allergy. Methods This prospective study enrolled 44 children aged 4–17 years with confirmed peanut allergy.
Klementyna Łyżwa, Magdalena Chojnowska‐Wójtowicz, Wioletta Zagórska, Marek Kulus, Katarzyna Grzela   +4 more
wiley   +1 more source